Cancer Care

Bladder Cancer -

• Phase II Trial Of Cisplatin, Gemcitabine and Bevacizumab in Combination For Metastatic Transitional Cell Cancer.

Breast Cancer -

• A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Flurouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), With or Without Celecoxib, in Patients With Node-Negative Breast Cancer.
• A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer.
• Program For The Assessment Of Clinical Cancer Tests (Pacct-1) Trial Assigning Individualized Options For Treatment
• Phase III Trial OF Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. (STAGES I, II, III)
• A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer.
• A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
• Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.
• A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team.
  

Colorectal Cancer -

• A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxiliplatin/5-FU/Leucovorin With Bevacizumab, or Cetuximab (c225), or With the Combination Of Bevacizumab and Cetuximab For Patients With Untreated Metastatic Adenocarcinoma Of the Colon or Rectum.

• A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.
  

Esophageal Cancer -

• A Phase II Study Of Temozolomide in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.

Head & Neck Cancer -

• A Phase II Study Of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.

Lung Cancer -

• A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>4cm) –IIIA Non-Small Cell Lung Cancer (NSCLC)

• A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer.

• Randomized Phase II Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy. 

• A Phase II Study Of Temozolomide in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation Of O6 –Methyl-Guanine-DNA Methyl Transferase (MGMT) Promoter.

Lymphoma -

• A Randomized Phase III Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin’s Lymphoma.
• A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (REVLIMID) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Myelodysplastic Syndrome -

• A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts).

Multiple Myeloma -

• Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation:  VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP).

Ovarian Cancer -

• A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis.

Prostate Cancer -

• Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer.

Renal Cancer -

• Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carninoma.